Clinical trials: CtDNA
Choroidal Melanoma
Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)
Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma
- Trial name
- ctDNA MU (NCT02875652)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Institut Curie
Colorectal Cancer, ctDNA
The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer
This study is to evaluate circulating tumor DNA (ctDNA) as a predictive and surveillant method for tumor recurrence in stage II and III colorectal cancer (CRC).
- Conditions
- Colorectal Cancer, ctDNA, Surveillance
- Trial name
- NCT03416478
- Testing
- ctDNA test
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Breast Neoplasms
Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients
In nonmetastatic local advanced breast cancer patients, we are going to investigate whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual…
- Trial name
- NCT03881384
- Testing
- ctDNA level during neoadjuant chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Appendiceal Adenocarcinoma, Colorectal
A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
To learn if circulating tumor DNA (ctDNA) testing before cytoreductive surgery (CRS) with or without heated intraperitoneal chemotherapy (HIPEC) can show if patients have a low or high risk of the disease returning and help…
- Trial name
- NCT05947838
- Testing
- Circulating tumoral DNA directed neoadjuvant therapy arm
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma
The aim of this study is to explore efficacy and safety of neoadjuvant nivolumab for non-metastatic upper tract urothelial carcinoma (UTUC), and explore the potential predictive biomarkers of immunotherapy.
- Trial name
- NCT05160285
- Testing
- Nivolumab 100 MG in 10 ML Injection
- Where
- Taiwan
- Volunteers
- 29 people
- Sponsor
- YULISU
Ovarian Cancer
Study of Circulating Tumoral DNA in Ovarian Cancer
Circulating tumor DNA detection and quantification in patients with ovarian cancer.
- Trial name
- NCT01350908
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Institut Curie
Gastric Cancer
Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
Gastric cancer (GC) is a leading global health problem and is the third most common cause of cancer related death. Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the mainstay treatment for locally advanced gastric…
- Trial name
- MENCA-GC (NCT03425058)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization.
- Trial name
- ECLIPSE (NCT04136002)
- Where
- 271 sites in United States
- Volunteers
- 44,467 people, healthy volunteers welcome
- Sponsor
- Guardant Health, Inc.
Esophageal Cancer, ctDNA
A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring
Esophageal squamous cell carcinoma (ESCC) continues to exhibit high incidence and mortality rates in China, with the majority of patients diagnosed at middle to advanced stages.
- Trial name
- NCT06792786
- Testing
- Induction Immunochemotherapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Central Hospital of Lishui City
Lymphoma, Lymphoma, B-Cell
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd…
- Trial name
- NCT06954805
- Testing
- Rituximab, Etoposide, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Jennifer Amengual
Non Small Cell Lung Cancer
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
Exploring the efficacy and safety of adaptively adjusting treatment regimens based on ctDNA (MRD) status for EGFR mutation-positive NSCLC
- Trial name
- NCT07661173
- Testing
- Firmonertinib, Firmonertinib/pemetrexed/Carboplatin, Firmonertinib/pemetrexed/Carboplatin/Bevacizumab
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Anhui Provincial Cancer Hospital
Colon Cancer
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
PEGASUS is a prospective multi-centric study designed to prove the feasibility of using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon…
- Trial name
- NCT04259944
- Testing
- CAPOX, Capecitabine, FOLFIRI
- Where
- 11 sites in Italy, Spain
- Volunteers
- 140 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Gastric Cancer, Circulating Tumor DNA (ctDNA)
Potential Clinical Utilities of Circulating Tumor DNA in Advanced HER2 Negative Gastric Cancer
This study aims to evaluate the use of next generation sequencing (NGS) to detect circulating tumor DNA in advanced HER2 negative gastric cancer patients.
- Trial name
- NCT05513144
- Where
- China
- Volunteers
- 30 people
- Sponsor
- chenwu
Advanced NSCLC, Circulating Tumor Cells
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation
- Conditions
- Advanced NSCLC, Circulating Tumor Cells, Circulating Tumor DNA
- Trial name
- NCT04229121
- Testing
- nonintervention
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Gastrointestinal Stromal Tumors
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's…
- Trial name
- NCT05366816
- Testing
- Sunitinib, Regorafenib
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Miami
High Grade Ovarian Serous Adenocarcinoma, High Grade Serous Carcinoma
Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
Chemotherapy resistance is the greatest contributor to mortality in advanced cancers and severe challenges remain in finding effective treatment modalities to cancer patients with metastasized and relapsed disease.
- Trial name
- DECIDER (NCT04846933)
- Testing
- WGS and RNA sequencing, circulating tumor DNA (ctDNA), FDG PET/CT imaging
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Turku University Hospital
Colorectal Neoplasms, Colorectal Neoplasms Malignant
Smart Measurement of Circulating Tumor DNA
The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages. Participants will be asked to take an extra blood test, which will be analyzed further in the lab.
- Conditions
- Colorectal Neoplasms, Colorectal Neoplasms Malignant, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Nonpolyposis Colon Cancer
- Trial name
- SMART (NCT06989814)
- Testing
- Blood Product
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Colorectal Cancer
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
- Trial name
- STELLAR-316 (NCT07750158)
- Testing
- Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 13 sites in United States
- Volunteers
- 600 people
- Sponsor
- Exelixis
Prostate Cancer
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Trial name
- CONCORD (NCT07052578)
- Where
- 28 sites in Russia
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Metastatic Melanoma, Advanced Melanoma
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival.
- Trial name
- NCT07504796
- Testing
- Nivolumab, Relatlimab, Ipilimumab
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- NYU Langone Health